Continuous Monitoring of Circadian Glycemic Patterns In Patients Receiving Prednisolone For COPD
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
CONTEXT: Endogenous glucocorticoid excess (Cushing's syndrome) predominantly increases postprandial glucose concentration. The pattern of hyperglycemia induced by prednisolone has not been well characterized. OBJECTIVE: Our objective was to define the circadian effect of prednisolone on glucose concentration to optimize management of prednisolone-induced hyperglycemia. DESIGN AND SETTING: This was a cross-sectional study in a teaching hospital. PARTICIPANTS: Participants included 60 consecutive consenting subjects with chronic obstructive pulmonary disease admitted to hospital: 13 without known diabetes admitted for other indications and not treated with glucocorticoids (group 1), 40 without known diabetes admitted with an exacerbation of chronic obstructive pulmonary disease and treated with prednisolone (group 2, prednisolone = 30 ± 6 mg/d), and seven with known diabetes treated with prednisolone (group 3, prednisolone = 26 ± 9 mg/d). MAIN OUTCOME MEASURE: Interstitial glucose concentration was assessed during continuous glucose monitoring. RESULTS: Significantly more subjects in group 2 [21 of 40 (53%), P = 0.02] and group 3 [seven of seven (100%), P = 0.003] recorded a glucose of at least 200 mg/dl (≥11.1 mmol/liter) during continuous glucose monitoring than in group 1 [one of 13 (8%)]. The mean glucose concentration between 2400-1200 h for group 3 (142 ± 36 mg/dl) was significantly greater than in the other two groups (P < 0.005), whereas mean glucose concentrations between 2400-1200 h in group 1 (108 ± 16 mg/dl) and group 2 (112 ± 22 mg/dl) were not significantly different. In contrast, the mean glucose concentrations between 1200-2400 h for group 2 (142 ± 25 mg/dl) and group 3 (189 ± 32 mg/dl) were both significantly greater than group 1 (117 ± 14 mg/dl, P < 0.05 for both comparisons). CONCLUSIONS: Prednisolone predominantly causes hyperglycemia in the afternoon and evening. Treatment of prednisolone-induced hyperglycemia should be targeted at this time period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rates of severe hypoglycemia events in ambulatory persons with end-stage kidney disease on dialysis are 10-fold higher than among other nondialysis persons with CKD and often associated with prolonged hypoglycemic episodes and poor response to regular hypoglycemia treatment.1375”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1375]
In the citing paper
“These findings are in line with previous reports of afternoon and evening hyperglycaemia under glucocorticoids in persons without DM.24 27 55”
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes
Umpierrez, G. E., Isaacs, S. D., Bazargan, N., You, X., Thaler, L. M., & Kitabchi, A. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8341 · Cited by 2,195
Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care · doi:10.2337/dc09-9029 · Cited by 1,444 · cited 3×
“As such, currently, we would not support routine glucose lowering in patients with mild prednisolone-induced hyperglycemia but recommend individualized decision making based on the severity and duration of hyperglycemia, aiming to maintain blood glucose from 72–180 mg/dl (4–10 mmol/liter), in line with general recomme…”
BackgroundInfluentialDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 1×
“However, endogenous glucocorticoid excess in Cushing’s syndrome predominantly increases postprandial blood glucose concentration with fasting glucose often in the normal range (8).”
BackgroundKrinsley, J. S. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.12.1471 · Cited by 1,165
Weir, C. J., Murray, G. D., Dyker, A. G., & Lees, K. R. (1997) · BMJ · doi:10.1136/bmj.314.7090.1303 · Cited by 522 · cited 2×
“Hyperglycemic Effect of Glucocorticoids J Clin Endocrinol Metab, June 2011, 96(6):1789–1796”
BackgroundGlucocorticoid-induced hyperglycemia
Clore, J. N., & Thurby-Hay, L. (2009) · Endocrine Practice · doi:10.4158/ep08331.rar · Cited by 508
Deedwania, P., Kosiborod, M., Barrett, E., Ceriello, A., Isley, W., Mazzone, T., & Raskin, P. (2008) · Circulation · doi:10.1161/circulationaha.107.188629 · Cited by 488
Limitations of Conventional Methods of Self-Monitoring of Blood Glucose
Boland, E., Monsod, T., Delucia, M., Brandt, C. A., Fernando, S., & Tamborlane, W. V. (2001) · Diabetes Care · doi:10.2337/diacare.24.11.1858 · Cited by 423 · cited 1×
“CGMS provide detailed information regarding nocturnal and postprandial glycemia, whereas standard finger-prick blood glucose monitoring regimens do not (11).”
BackgroundBaker, E. H. (2006) · Thorax · doi:10.1136/thx.2005.051029 · Cited by 418
Cited by
Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E. D., Leigh, R., Brown, J. P., Cohen, A., & Kim, H. (2013) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-9-30 · Cited by 1,268
“GCs also appear to have a greater impact on postprandial compared to fasting glucose levels [37].”
BackgroundCavaillès, A., Brinchault-Rabin, G., Dixmier, A., Goupil, F., Gut-Gobert, C., Marchand-Adam, S., Meurice, J.-C., Morel, H., Person-Tacnet, C., Leroyer, C., et al. (2013) · European Respiratory Review · doi:10.1183/09059180.00008612 · Cited by 510
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Steroid‐induced diabetes: a clinical and molecular approach to understanding and treatment
Hwang, J. L., & Weiss, R. E. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2486 · Cited by 380
“reported 12-year graft survival in diabetic patients to be 48% versus 70% in controls [33].”
BackgroundInfluentialProgress in the mechanism and targeted drug therapy for COPD
Wang, C., Zhou, J., Wang, J., Li, S., Fukunaga, A., Yodoi, J., & Tian, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00345-x · Cited by 303
Systemic Glucocorticoid Therapy: a Review of its Metabolic and Cardiovascular Adverse Events
Fardet, L., & Fève, B. (2014) · Drugs · doi:10.1007/s40265-014-0282-9 · Cited by 236
“It seems more appropriate to measure postprandial blood glucose concentration [64, 71, 72].”
BackgroundGlucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem
Suh, S., & Park, M. K. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.180 · Cited by 227
9. pharmacologic approaches to glycemic treatment: standards of care in diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s009 · Cited by 263
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“…therapy should be started when pre-or post-prandial glucose repeatedly exceed 140 mg/dL (7.8 mmol/L) or 200 mg/dL (11.1 mmol/L), respectively (399-401), and similar treatment strategies used in patients with T2D, including a stepwise intensification of anti-hyperglycemic therapy as well as…”
MethodInfluential16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s016 · Cited by 195
Diabetes in Cushing syndrome: basic and clinical aspects
Mazziotti, G., Gazzaruso, C., & Giustina, A. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.001 · Cited by 193
Galindo, R. J., Migdal, A. L., Davis, G. M., Urrutia, M. A., Albury, B., Zambrano, C., Vellanki, P., Pasquel, F. J., Fayfman, M., Peng, L., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2073 · Cited by 181
“Prior studies in the non–critically ill hospitalized population were performed with previous CGM technology (7,22,23,28) requiring capillary glucose for calibration, including MedtronicMiniMedGold andMedtronic iPro2, reporting up to 91.”
MethodGlucocorticoids and Type 2 Diabetes: From Physiology to Pathology
Di Dalmazi, G., Pagotto, U., Pasquali, R., & Vicennati, V. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/525093 · Cited by 168
“This seems to be true also for patients taking exogenous glucocorticoids, in whom high glycemic values were shown to occur in the afternoon and in the evening [45].”
BackgroundPrevention and management of glucocorticoid-induced side effects: A comprehensive review
Caplan, A., Fett, N., Rosenbach, M., Werth, V. P., & Micheletti, R. G. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.02.1241 · Cited by 168
Prevention and management of glucocorticoid-induced side effects: A comprehensive review
Caplan, A. S., Fett, N. M., Rosenbach, M. A., Werth, V. P., & Micheletti, R. G. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.01.062 · Cited by 178
Chronic Obstructive Pulmonary Disease and Diabetes Mellitus: A Systematic Review of the Literature
Gläser, S., Krüger, S., Merkel, M., Bramlage, P., & Herth, F. J. F. (2015) · Respiration · doi:10.1159/000369863 · Cited by 153
Chronopharmacology of glucocorticoids
Scherholz, M. L., Schlesinger, N., & Androulakis, I. P. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.004 · Cited by 144
“Similar findings were observed for patients receiving prednisolone to treat COPD [158].”
ResultInfluentialThe Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity
Lockett, J., Inder, W. J., & Clifton, V. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae008 · Cited by 135
Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony
Mirrakhimov, A. E. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-132 · Cited by 148
“showed that patients with COPD treated with systemic corticosteroids had a circadian rise of glucose predominantly in the afternoon and evening [139].”
BackgroundThe high incidence of steroid-induced hyperglycaemia in hospital
Fong, A. C., & Cheung, N. W. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.12.023 · Cited by 109
“A recent study using continuous glucose monitoring found that 53% of patients receiving prednisone for chronic obstructive pulmonary disease had at least one episode of hyperglycaemia, defined as a glucose level 10 mmol/L [12].”
BackgroundResultInfluentialSteroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review
Bonaventura, A., & Montecucco, F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.006 · Cited by 108
Glucocorticoid-induced diabetes and adrenal suppression: How to detect and manage them
Lansang, M. C., & Hustak, L. K. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10180 · Cited by 105
Prevention and management of glucocorticoid-induced side effects: A comprehensive review
Caplan, A. S., Fett, N. M., Rosenbach, M. A., Werth, V. P., & Micheletti, R. G. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.02.1239 · Cited by 117
“In an observational study of patients receiving prednisolone for chronic obstructive pulmonary disease, the use of continuous blood glucose monitoring demonstrated hyperglycemia predominantly occurring in the afternoon and evening.(20) Risk factors for steroid-induced diabetes include older age and higher body mass in…”
BackgroundPernicova, I., Kelly, S., Ajodha, S., Sahdev, A., Bestwick, J. P., Gabrovska, P., Akanle, O., Ajjan, R., Kola, B., Stadler, M., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30021-8 · Cited by 89
Burt, M. G., Roberts, G. W., Aguilar-Loza, N. R., & Stranks, S. N. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0282 · Cited by 83
Self-citation16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s016 · Cited by 80
Hitchings, A. W., Lai, D., Jones, P., & Baker, E. H. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-208035 · Cited by 82
Kulkarni, S., Durham, H., Glover, L., Ather, O., Phillips, V., Nemes, S., Cousens, L., Blomgran, P., & Ambery, P. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061476 · Cited by 69
Kauh, E., Mixson, L., Malice, M.-P., Mesens, S., Ramael, S., Burke, J., Reynders, T., Van Dyck, K., Beals, C., Rosenberg, E., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0751 · Cited by 69
Management of the COPD Patient with Comorbidities: An Experts Recommendation Document
Iglesias, J. R., Díez‐Manglano, J., García, F. L., Peromingo, J. A. D., Almagro, P., & Aguilar, J. M. V. (2020) · International Journal of COPD · doi:10.2147/copd.s242009 · Cited by 83
Glucocorticoid-Induced Hyperglycemia: A Neglected Problem
Cho, J.-H., & Suh, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1951 · Cited by 63
“diate-acting glucocorticoid like prednisolone align with the late peak and prolonged action of NPH insulin [79], a once-daily morning regimen combining an intermediate-acting glucocorticoid with NPH is a sensible approach.”
BackgroundYates, C. J., Fourlanos, S., Colman, P. G., & Cohney, S. J. (2013) · Transplantation · doi:10.1097/tp.0b013e3182a012f3 · Cited by 60
“Performing afternoon glucose testing captures the maximal effect of prednisolone on glycemia, which occurs approximately 7 to 8 hr after dosing (9, 10).”
BackgroundYuen, K. C. J., McDaniel, P. A., & Riddle, M. C. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04242.x · Cited by 58
Burt, M. G., Willenberg, V., Petersons, C. J., Smith, M., Ahern, M. J., & Stranks, S. N. (2012) · Rheumatology · doi:10.1093/rheumatology/kes003 · Cited by 64
Self-citationManagement of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotide
Reznik, Y., Bertherat, J. Y., Borson‐Chazot, F., Brue, T. C., Chanson, P., Cortet‐Rudelli, C., Delemer, B., Tabarin, A., Bisot-Locard, S., & Vergès, B. L. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.10.005 · Cited by 61
Lenferink, A., Frith, P. A., van der Valk, P., Buckman, J., Sladek, R., Cafarella, P., van der Palen, J. A. M., & Effing, T. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.06.003 · Cited by 58
“increased anxiety during an exacerbation and steroid-induced hyperglycaemia [48]).”
BackgroundSelf-citationRadhakutty, A., & Burt, M. G. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0315 · Cited by 50
Self-citationEffect of Inhaled Corticosteroids on Glycemic Status
Egbuonu, F., Antonio, F. A., & Edavalath, M. (2014) · The Open Respiratory Medicine Journal · doi:10.2174/1874306401408010101 · Cited by 51
“Studies showed that the glycemic rise related to steroid therapy usually begins 4 hours after the dose and usually persists for up to 16 hours [25, 30].”
Lakhani, O., Kumar, S., Tripathi, S., Desai, M., & Seth, C. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_226_17 · Cited by 43
“The nondiabetic cohort in the study by Burt et al., who received glucocorticoids, developed a hyperglycemic peak after 6–8 h despite not having a significant postprandial glycemic surge.”
BackgroundResultInfluentialYates, C. J., Fourlanos, S., Colman, P. G., & Cohney, S. J. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft377 · Cited by 42
“3 mmol/L (204 mg/dL) occurred at 15:30 h [22].”
Side Effects of Glucocorticoids
ALAN, İ. S., & Alan, B. (2018) · InTech eBooks · doi:10.5772/intechopen.72019 · Cited by 42
Gerards, M. C., Venema, G. E., Patberg, K. W., Kross, M., Potter van Loon, B. J., Hageman, I. M. G., Snijders, D., Brandjes, D. P. M., Hoekstra, J. B. L., Vriesendorp, T. M., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13209 · Cited by 39
“82% of patients without pre-existing diabetes, and in 96% to 100% of patients with pre-existing diabetes.(1) Hyperglycaemia during”
BackgroundBaldwin, D., & Apel, J. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0339-7 · Cited by 42
1,5-Anhydroglucitol and Glycated Albumin in Glycemia
Koga, M. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800263-6.00007-0 · Cited by 44
Burt, M. G., Drake, S. M., Aguilar‐Loza, N. R., Esterman, A., Stranks, S. N., & Roberts, G. W. (2015) · Internal Medicine Journal · doi:10.1111/imj.12680 · Cited by 38
Self-citationRadhakutty, A., Stranks, J. L., Mangelsdorf, B. L., Drake, S. M., Roberts, G. W., Zimmermann, A. T., Stranks, S. N., Thompson, C. H., & Burt, M. G. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12859 · Cited by 38
Self-citationWhen therapeutic drugs lead to diabetes
Fève, B., & Scheen, A. J. (2022) · Diabetologia · doi:10.1007/s00125-022-05666-w · Cited by 43
“Continuous blood glucose monitoring has shown that hyperglycaemia occurs in the afternoon and evening [8], particularly with intermediate-acting GCs (prednisone, prednisolone, methylprednisolone) given as single morning doses (the most frequently prescribed regimen).”
BackgroundHyperglycemia and Diabetes Mellitus Following Organ Transplantation
Galindo, R. J., & Wallia, A. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0707-1 · Cited by 39
Verma, A. K., Bhatt, D., Goyal, Y., Dev, K., Beg, M. M. A., Alsahli, M. A., & Rahmani, A. H. (2021) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s285469 · Cited by 43
“Glucocorticoids (GC) deteriorate glucose tolerance through various pathways by inhibiting glucose uptake in the adipose tissue and increasing hepatic gluconeogenesis.(56) GCs were found to be associated with different levels of dysfunction of β cells, decrease in the insulin sensitivity as well as reduced β cell funct…”
BackgroundManagement issues with exogenous steroid therapy
Bandgar, T., Patt, H., Lila, A. R., & Shah, N. S. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.123548 · Cited by 46
“Postprandial glucose is more commonly deranged compared to fasting glucose levels.[13] Fasting hyperglycemia can be seen in patients receiving higher once‐daily GC doses or twice‐daily dosing or with dexamethasone.”
BackgroundMatsuo, K., Nambu, T., Matsuda, Y., Kanai, Y., Yonemitsu, S., Muro, S., & Oki, S. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.8622 · Cited by 35
Peng, Y., Zhong, G., Wang, L., Guan, L., Wang, A., Hu, K., & Shen, J. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1178-y · Cited by 39
“In addition, a predominant circadian cycle of hyperglycaemia in the afternoon and evening has been found in COPD patients prescribed prednisolone [47].”
BackgroundSilvestris, N., Franchina, T., Gallo, M., Argentiero, A., Avogaro, A., Cirino, G., Colao, A. A. L., Danesi, R., Cianni, G. D., D’Oronzo, S., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102062 · Cited by 38
“…it causes only a mild increase in fasting blood glucose levels, a large increase in postprandial blood glucose both in patients with and without pre-existing DM, 27 predominantly occurring in the afternoon and evening, 27 and impaired sensitivity to exogenous insulin 28 are frequently observed.”
BackgroundRhou, Y. J. J., Hor, A., Wang, M., Wu, Y., Jose, S., Chipps, D. R., & Cheung, N. W. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110151 · Cited by 34
“Prior to the COVID-19 pandemic, clinical experience and study data were most extensive for prednisolone-induced hyperglycaemia, characterised by a rise from 3-4 h, peak at 5–8 h and duration of 12–16 h [5].”
BackgroundTatalovic, M., Lehmann, R., Cheetham, M., Nowak, A., Battegay, E., & Rampini, S. K. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-028914 · Cited by 27
Diabetes Mellitus and Chronic Obstructive Pulmonary Disease: An Overview
Katsiki, N., Steiropoulos, P., Παπάνας, Ν., & Mikhailidis, D. P. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1038-3883 · Cited by 42
“[23] Burt MG, Roberts GW, Aguilar-Loza NR et al.”
BackgroundOlsen, M. T., Dungu, A. M., Klarskov, C. K., Jensen, A. K., Lindegaard, B., & Kristensen, P. L. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-01874-7 · Cited by 27
“patients with diabetes) are linked to an increased risk of developing GIH [5] and that glycemic excursion in patients with diabetes and treated with GCs due to COPD in acute exacerbation are higher than for patients without diabetes measured by CGM [29].”
BackgroundBurt, M. G., Roberts, G. W., Aguilar-Loza, N. R., Quinn, S. J., Frith, P. A., & Stranks, S. N. (2013) · Internal Medicine Journal · doi:10.1111/imj.12157 · Cited by 27
Self-citationKhowaja, A., Alkhaddo, J. B., Rana, Z., & Fish, L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0468-3 · Cited by 25
Hegelund-Myrbäck, T., Prothon, S., Edman, K., Leander, J., Hashemi, M., Dearman, M. S., Edenro, G., Svanberg, P., Andersson, E.-M., Almquist, J., et al. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30103-1 · Cited by 32
Uchinuma, H., Ichijo, M., Harima, N., & Tsuchiya, K. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0542-5 · Cited by 22
Mazziotti, G., Maffezzoni, F., Doga, M., Hofbauer, L. C., Adler, R. A., & Giustina, A. (2014) · Bone · doi:10.1016/j.bone.2014.07.008 · Cited by 24
“In patients treated with teriparatide, however, serumHbA1c decreased significantly, whereas fasting plasma glucose remained stable during the follow-up period, according to the concept that fasting plasma glucose may not be a reliable marker of glucose homeostasis in patients exposed to glucocorticoid excess [30].”
BackgroundGerards, M. C., de Maar, J. S., Steenbruggen, T. G., Hoekstra, J. B. L., Vriesendorp, T. M., & Gerdes, V. E. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12694 · Cited by 22
“Glucocorticoid therapy provokes hyperglycaemia in 46–100% of patients with diabetes, and in 40–70% of patients without known diabetes [1,2].”
BackgroundLindberg-Larsen, V., Kehlet, H., Bagger, J., & Madsbad, S. (2018) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000003591 · Cited by 22
Optimal Timing of Glucose Measurements After Total Joint Arthroplasty
Varady, N. H., Schwab, P., Jones, T., Collins, J. E., Fitz, W., & Chen, A. F. (2019) · The Journal of Arthroplasty · doi:10.1016/j.arth.2019.01.004 · Cited by 23
Ito, S., Ogishima, H., Kondo, Y., Sugihara, M., Hayashi, T., Chino, Y., Goto, D., Matsumoto, I., & Sumida, T. (2013) · Modern Rheumatology · doi:10.3109/14397595.2013.852855 · Cited by 27
Habib, G. S., Dar-Esaif, Y., Bishara, H., Artul, S., Badarny, S., Chernin, M., & Jabbour, A. R. (2014) · Respiratory Medicine · doi:10.1016/j.rmed.2014.08.006 · Cited by 22
Nugent, K., Islam, E. A., Limsuwat, C., Nantsupawat, T., & Berdine, G. G. (2015) · Annals of Thoracic Medicine · doi:10.4103/1817-1737.151439 · Cited by 24
“Glucose levels have a circadian pattern with higher values in the late afternoon in corticosteroid treated patients with AECOPD, and routine morning lab tests may not detect the range of glucose elevations.[18,19] In addition, glycemic variability is associated with increased length of stay and mortality in hospitaliz…”
BackgroundBauerle, K. T., & Harris, C. A. (2016) · Europe PMC (PubMed Central) · Cited by 31
Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment
Mulla, K., Farag, S., Moore, B., Matharu, S. S., Young, K., Larkin, J., Popat, S., & Morganstein, D. L. (2023) · Diabetic Medicine · doi:10.1111/dme.15053 · Cited by 19
Drug-induced hyperglycemia and diabetes
Heurtebize, M.-A., & Faillie, J. (2023) · Therapies · doi:10.1016/j.therap.2023.09.010 · Cited by 21
The pharmacological treatment of chronic comorbidities in COPD: mind the gap!
Gentilucci, U. V., Pedone, C., Muley, M., & Incalzi, R. A. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.06.004 · Cited by 20
Steroid-induced hyperglycaemia in hospitalised patients: does it matter?
Cheung, N. W. (2016) · Diabetologia · doi:10.1007/s00125-016-4116-z · Cited by 19
“In studies where glucose levels were tested systematically amongst patients treated with high dose prednisone or prednisolone in hospital, 53–70% of nondiabetic individuals developed hyperglycaemia [3, 4].”
BackgroundKishimoto, M., & Noda, M. (2015) · The Journal of Medical Investigation · doi:10.2152/jmi.62.1 · Cited by 21
Glucocorticoid‐induced hyperglycaemia in respiratory disease: a systematic review and meta‐analysis
Breakey, S., Sharp, S. J., Adler, A., & Challis, B. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12739 · Cited by 17
“It has been shown that glucocorticoids administered in the morning increase the value of blood glucose into the evening, peaking 8 hours later, diminishing overnight, and resulting in normal fasting glucose levels the following morning.(15) In summary, the data suggest that glucocorticoids increase the risk of hypergl…”
How should rheumatologists manage glucocorticoid-induced hyperglycemia?
Nakamura, H., Fujieda, Y., Nakamura, A., & Atsumi, T. (2020) · Modern Rheumatology · doi:10.1080/14397595.2020.1823060 · Cited by 20
“disposes the patient to hyperglycemia later in the day [34,35].”
BackgroundCorticosteroid refractory sarcoidosis
Goldman, C., & Judson, M. A. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106081 · Cited by 17
Nowak, K. M., Rdzanek, M., Romanowska‐Próchnicka, K., Nowakowska-Płaza, A., & Papierska, L. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa724 · Cited by 17
Miyawaki, Y., Katsuyama, T., Sada, K., Hiramatsu, S., Ohashi, K., Morishita, M., Katsuyama, E., Watanabe, H., Takano-Narazaki, M., Tatebe, N. T., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178018 · Cited by 16
Metformin's effectiveness in preventing prednisone-induced hyperglycemia in hematological cancers
Ochola, L. A., Nyamu, D. G., Guantai, E. M., & Weru, I. W. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219873048 · Cited by 16
“Studies have demonstrated the occurrence of PIH predominantly in the afternoon and evening, suggesting that this serves as the most appropriate screening and treatment intervention time.(20) Uzu et al.”
BackgroundKatsuyama, H., Sako, A., Adachi, H., Hamasaki, H., & Yanai, H. (2015) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2153w · Cited by 16
“Glucocorticoid-induced insulin resistance and pancreatic islet-cell dysfunction lead to mild increase in fasting plasma glucose levels and a greater increase in postprandial glucose levels [4-9].”
Backgroundvan Laar, J. M., Lei, A., Safy‐Khan, M., Almquist, J., Belfield, G., Edman, K., Öberg, L., Angermann, B., Dillmann, I., Berntsson, P., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13624 · Cited by 14
“6,21 Reduced disruption of glycemic control with AZD9567 versus prednisolone was evident in a healthy volunteer study: with AZD9567 doses up to 80 mg, plasma glucose after an oral glucose tolerance test was similar to that observed with prednisolone 5 mg. 6 The effects of the study drugs on…”
MethodIncompatibility between fasting and postprandial plasma glucose in patients with Cushing’s syndrome
Otsuki, M., Kitamura, T., Tamada, D., Tabuchi, Y., Mukai, K., Morita, S., Kasayama, S., Shimomura, I., & Koga, M. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej15-0748 · Cited by 15
Shacham, E. C., Kfir, H., Schwartz, N., & Ishay, A. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0300-0 · Cited by 15
Klarskov, C. K., Schultz, H. H., Persson, F., Christensen, T. M., Almdal, T., Snorgaard, O., Hansen, K. B., Pedersen‐Bjergaard, U., & Kristensen, P. L. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00561-0 · Cited by 13
Glucocorticoid-induced hyperglycemia and diabetes: Practical points
Descours, M., & Rigalleau, V. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.03.011 · Cited by 19
Lyall, M. J., Thethy, I., Steven, L., Mackean, M., Nussey, F., Sakala, M., Rye, T., Strachan, M. W. J., & Dover, A. R. (2018) · Diabetic Medicine · doi:10.1111/dme.13770 · Cited by 19
Jin, H. Y., Lee, K. A., Kim, Y. J., Park, T. S., Lee, S., Park, S. K., Hwang, H. P., Yang, J. D., Ahn, S.-W., & Yu, H. C. (2019) · Journal of Diabetes Research · doi:10.1155/2019/1757182 · Cited by 19
“Of course, our data also showed a similar pattern of hyperglycemia to those in previous studies, with an increase from midmorning to afternoon until early evening due to morning glucocorticoid administration [24, 25].”
ResultThe Effect of Different Glycaemic States on Renal Transplant Outcomes
Sheu, A., Depczynski, B., O’Sullivan, A., Luxton, G., & Mangos, G. (2016) · Journal of Diabetes Research · doi:10.1155/2016/8735782 · Cited by 15
Post-transplantation diabetes mellitus in pediatric patients
Grundman, J. B., Wolfsdorf, J. I., & Marks, B. E. (2020) · Hormone Research in Paediatrics · doi:10.1159/000514988 · Cited by 12
Gerards, M. C., Tervaert, E. C. C., Hoekstra, J. B. L., Vriesendorp, T. M., & Gerdes, V. E. A. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.040 · Cited by 18
“be targeted at afternoon and evening hours during which hyperglycaemia is more pronounced [32].”
BackgroundHerth, F. J. F., Bramlage, P., & Müller‐Wieland, D. (2014) · Respiration · doi:10.1159/000368371 · Cited by 14
Abordagem e Tratamento da Hiperglicemia Induzida por Glicocorticóides
Paredes, S., & Alves, M. (2016) · Acta Médica Portuguesa · doi:10.20344/amp.7758 · Cited by 67
Care of Children and Adolescents with Diabetes Mellitus and Hyperglycemia in the Inpatient Setting
Kharode, I., Coppedge, E., & Antal, Z. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1205-7 · Cited by 15
Cheng, Y.-C., Guerra, Y., Morkos, M., Tahsin, B., Onyenwenyi, C., Fogg, L., & Fogelfeld, L. (2021) · PLOS ONE · doi:10.1371/journal.pone.0256682 · Cited by 12
“However, GC effects on fasting hyperglycemia are only mild [10, 13, 14].”
BackgroundAn unexpectedly high prevalence of undiagnosed diabetes in patients awaiting lung transplantation
Hackman, K. L., Snell, G. I., & Bach, L. A. (2012) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2012.10.010 · Cited by 13
Glucocorticoid‐induced hyperglycaemia in hospitalised adults: A matched cohort study (2013–2023)
Golubić, R., Mumbole, H., Coleman, R. L., Rea, R. D., Mathur, R., Caleyachetty, R., & Adler, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16378 · Cited by 13
“15 Epidemiologic studies focusing on GIH and its risk factors among inpatients were conducted on small samples of patients with a single category of conditions including inflammatory bowel disease, 14 respiratory diseases 9,13 and haematologic malignancies.”
Cansu, G. B., Cansu, D. Ü., Taşkıran, B., Bilge, Ş. Y., Bilgin, M., & Korkmaz, C. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.03.012 · Cited by 12
COPD exacerbations in general practice: variability in oral prednisolone courses
de Vries, M., Berendsen, A. J., Bosveld, H. E. P., Kerstjens, H. A. M., & van der Molen, T. (2012) · BMC Family Practice · doi:10.1186/1471-2296-13-3 · Cited by 11
“1 mmol/l) within 24 hours [23].”
Effing, T., Lenferink, A., Buckman, J., Spicer, D. D. M., Cafarella, P., Burt, M. G., Bassett, K. L., van Ommeren, C., Anesbury, S., van der Valk, P. D. L. P. M., et al. (2014) · PubMed · doi:10.3978/j.issn.2072-1439.2014.11.14 · Cited by 12
“Hyperglycaemia in patients treated with prednisolone predominantly occurs between midday and midnight (31).”
BackgroundSelf-citation
Metadata
- Authors
- Burt, M. G., Roberts, G. W., Aguilar-Loza, N. R., Frith, P., & Stranks, S. N.
- Affiliations
- Flinders University (AU)
- Repatriation General Hospital (AU)
- Corresponding author
- Burt, Morton G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-06
- Volume
- 96
- Issue
- 6
- Pages
- 1789-1796
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2042010542
- Cited by
- 203
- References
- 22
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 14 · 2022: 12 · 2021: 16 · 2020: 25 · 2019: 14 · 2018: 17 · 2017: 10 · 2016: 13 · 2015: 9 · 2014: 13 · 2013: 18 · 2012: 8
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- prednisolone, glucocorticoid-induced hyperglycemia, Cushing's syndrome, chronic obstructive pulmonary disease, COPD exacerbations, continuous glucose monitoring, interstitial glucose, postprandial hyperglycemia, diabetes mellitus, glucocorticoid adverse effects, timing of corticosteroid administration
- MeSH terms
- Aged, Aged, 80 and over, Anti-Inflammatory Agents, Blood Glucose, Cross-Sectional Studies, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Male, Middle Aged, Prednisolone, Prospective Studies, Blood Glucose Self-Monitoring, Patient Selection, Postprandial Period, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.